1 January 1 HBM Pharma/Biotech M&A Report 14 including in-depth analysis of trade sales of US and European biopharma companies backed by venture- and private-equity investors Key Findings $1.4 billion wordwide biopharma M&A transaction volume (including completed and announced deals, asset deals, acquisitions of divisions) $1. billion upfront transaction volume of completed US and European biopharma company trade sales (up from $4. billion in 1). $7.7 billion overall deal value including contingent payments Additional $7. billion value of announced US & European transactions (including the $ billion acquisition of Allergan by Actavis and the $.4 billion purchase of Cubist by Merck & Co.) Further $4. billion worth of transactions involving assets or divisions of US and European companies $1. billion deal volume of biopharma acquisitions outside of the US and Europe (ROW) Mid-sized biopharma companies spent substantially more on acquisitions than traditional large pharma firms Best-ever exit year over last decade for VC-backed US biopharma companies About the HBM Pharma/Biotech M&A Report The HBM Pharma/Biotech M&A Report covers all completed trade sales of US and European biotechnology and pharma companies with a therapeutic focus (Rx incl. generics as well as OTC). For 14, additional data for asset deals and transactions outside of US and Europe is provided. The report does not cover nutritional supplements, diagnostics, medical technology, life sciences tools, CROs, pharma manufacturing and services. Thus, we focus on the therapeutic drugs sector. Reverse mergers, minority investments and the purchase of assets or divisions are not included in the survey up to 1. Acquisitions that were structured as mergers for tax or other reasons are included. Unless mentioned otherwise, transaction value is defined in this report as the upfront consideration in cash and/or shares. By contrast, the overall or total transaction value also includes contingent ( biodollar ) payments linked to reaching certain milestones. Additional data such as investment by venture and private equity investors, exit multiples, stage of lead product etc were collected from various sources. Please note that such data may be based on estimates and may not have been available for all transactions. Also, the results presented in this report may deviate from our earlier reports due to subsequent reclassification or correction of data. Further information about the HBM Pharma/Biotech M&A Report including a list of all transactions can be found under The use of data and charts is permitted with reference to Pharma/Biotech M&A Report. The authors of the report welcome any feedback or corrections: Dr. Ulrich Geilinger, Dr. Chandra Leo, and Emil Bujak, 1
2 HBM Pharma/Biotech Report 14 Overview Biopharma M&A -14 Upfront Transaction Volume of Biopharma M&A Chart 1: Biopharma M&A Transaction Volumes -14 Upfront Transaction Volume ($ billion) Number of company trade sales US & Europe US companies acquired European companies acquired Total upfront deal volume (including announced deals) Acquisitions in ROW Purchase of assets/divisions US & Europe Announced acquisitions US & Europe Completed.4 company 7. trade sales.4 US & Europe $1. billion upfront transaction volume of completed US and European biopharma company trade sales (up from $4. billion in 1). $7.7 billion overall deal value including contingent payments. Additional $7. billion deal value of announced a transactions (including the $ billion acquisition of Allergan by Actavis and the $.4 billion purchase of Cubist by Merck & Co). Further $4. billion worth of transactions involving assets or divisions of US and European companies (Novartis-GSK asset swap grabbing the most headlines). $1. billion deal value of biopharma acquisitions outside of the US and Europe (ROW) In total, this amounts to $1.4 billion in overall biopharma deal value (including announced deals, asset deals, ROW deals) b. Largest completed company trade sales in 14: $ billion acquisition of Forest by Actavis, $. billion acquisition of Intermune by Roche, $.4 billion acquisition of Questcor by Mallinckrodt. Four asset deals (including sales of divisions) with a value of over $ billion each. See next page for list of largest biopharma M&A transactions in 14. Please note that our M&A data up to 1 do not cover asset deals or the sale of divisions, and the comparisons to previous years (pages 4ff.) only relate to trade sales of (entire) US and European biopharma companies with a therapeutic focus. a b but not completed by year end Other pharma-related transactions (manufacturing, API, packaging, services, diagnostics etc.) are not included in our statistics.
3 HBM Pharma/Biotech Report 14 Table 1: Largest Biopharma M&A Transactions During 14 Notes: * Announced transactions, not completed yet at year end 14 Asset/Div. includes sale of assets, products, divisions and subsidiaries Transactions ranked by upfront value
4 # of Transactions HBM Pharma/Biotech Report 14 Trade sales of public & private US & European biopharma companies Biopharma Trade Sales With Upfront >=$1 million Chart : Significant US and European Biopharma Trade Sales (Upfront of at least $1 million) # of transactions >=$1 billion Trade sales of public and private US and European biopharma companies, not including asset deals or purchase of divisions # of transactions >=$1 million US public US private Europe public Europe private 4 US transaction volume more than doubled from $7. billion in 1 to $.4 billion in 14 (see Chart 1). European deal volume dropped from $1. billion to $1.4 billion (see Chart 1). Highest number of $1 billion plus transactions since (14 transactions a, mostly US targets). Highest number of larger acquisitions of private companies since (4 transactions with upfront of at least $1 million). Increase of number of US deals with upfront of $1 million or more. Stable number in Europe. a Not including $1 billion plus transactions outside of US and Europe (Ranbaxy / Sun Pharma $. billion, CFR / Abbott $. billion, Paladin / Endo $.7 billion) 4
5 Average Premium Paid for Public Takeovers HBM Pharma/Biotech Report 14 Premiums Paid for Public Biopharma Companies Trade sales of public US & European biopharma companies Average Premiums Paid for Public BioPharma Companies Chart : Premiums Paid for US and European Public Biopharma Companies % % 7% % % 4% 4% 4% 4% % % 1% US and European public takeovers with upfront consideration of at least $1 million 7% 4% 4% 4% 4% US deals % 1% % 7% US & European deals European deals % 4% 47% % % % 4% 4% 4% % % 7% % % % 1% % Trade sales of public US and European biopharma companies with an upfront consideration of at least $1 million. Comment: Premium = increase of stock price on the day of deal announcement. Only deals with an upfront consideration of at least $1 million are included. High degree of variation in premiums paid. As usual, average numbers should be interpreted with caution. 1% average premium paid for public biopharma companies in 14 (up from % in 1). Premiums paid in the US are generally higher than in Europe. European premiums have been trending downwards since to around %. US premiums jumped back to % from a low of 7% in 1.
6 HBM Pharma/Biotech Report 14 Trade sales of public US & European biopharma companies Chart 4: Average Premiums Premiums Paid forpaid Public for BioPharma Public Biopharma Companies Companies % Premium Paid %.7% US and European public takeovers with upfront consideration of at least $1 million.% 7.7%.% % 4% % 4.% 7.4% % Average Phase II Phase III Approved/ marketed Large pharma buyers Anti- Infectives Trade sales of public US and European biopharma companies 1-14 with an upfront consideration of at least $1 million. Premium = increase Source: HBM of stock Pharma/Biotech price at day M&A of Report announcement. No significant correlation of premium paid and transaction size was observed. Clinical-stage companies generally received higher premiums than companies with approved or marketed products. No significant differences in premiums paid across various therapeutic areas with the exception of anti-infectives. Premiums for anti-infectives companies averaged over % for years 1 to 14 (due to very high premiums paid for some anti-viral companies). Large pharma buyers on average paid higher premiums than other buyers. This also holds true if we control for the stage of companies acquired.
7 Upfront Transaction Value ($ billion) HBM Pharma/Biotech Report 14 Location of Buyers Trade sales ofpublic & private US & European biopharma companies Biopharma Trade Sales - Location of Buyers Chart : Location of Buyers of US and European Biopharma Companies Canada & ROW Japan & Asia US Europe Incl. Pfizer/Wyeth Merck/Schering P. $1.7 billion Companies headquartered in Ireland Trade sales of public and private US and European biopharma companies, not including asset deals or purchase of divisions 1 In 1 and 1, US firms were the dominant buyers. In 14, acquisitions by European firms generated the bulk of deal volume. (It should be noted, however, that European companies here include active buyers such as Actavis, Perrigo or Endo which are domiciled in Ireland mainly for tax purposes.) As in most previous years, buyers located in other parts of the world such as Japan did not spend significant amounts on US or European acquisitions in 14. Therapeutic Areas M&A activity in oncology was very strong in 1 with an upfront transaction volume of $1.4 billion in 1 deals. In 14, the 11 oncology-related transactions generated a comparatively modest $ billion of deal value. Fewer transactions than in oncology, but higher overall deal values were seen in autoimmune/ inflammation ($11. billion), respiratory ($. billion) and anti-infectives ($. billion). Note: Forest s $ billion sale is not included in this analysis. In the very active orphan drug space, 7 transactions generated $14. billion of deal volume, while 11 generics/otc companies were sold for a total of $.7 billion in 14. 7
8 % of Total Upfront Transaction Value HBM Pharma/Biotech Report 14 Transaction Volume by Type of Buyers Trade sales of public & private US & European biopharma companies Share of Upfront Transaction Value by Buyer Size/Type Chart : Share of Upfront Transaction Value by Type/Size of Buyer 1% % % 4% % % 1% 7% % 11% % % 1% % % % 7% 1% 1% % % % 17% 1% % % 1% 1% 11% 7% % % 1% 4% % % 74% 7% % % % 4% % % % % Smaller biopharma Large biotech Mid-sized pharma Large pharma Including announced deals & asset purchases Trade sales of public and private US and European biopharma companies. Large pharma companies are incumbent large pharma companies ranked within the top biopharma companies by 1 sales. Large biotech companies: Amgen, Biogen Idec, Celgene, Genentech (now Roche), Genzyme (now Sanofi) and Gilead. Mid-sized pharma companies are biopharma companies (outside of the categories Large pharma and Large biotech ) that rank within the top biopharma companies by 1 sales (usually with a market cap of $1 billion or higher). Smaller biopharma companies are all other companies. Other buyers (delta to 1%) were companies with their main business outside of pharma (such food, chemicals or diversified firms) and private-equity funds. Mid-sized pharma companies such as Actavis, Shire, etc. were the most important buyers in 14 with a ~% share of deal value. Large pharma s share of transaction volume in 14 increased over 1, but is still historically low compared to the years -11. Smaller biopharma companies bought other companies representing a share of deal volume below 1%. Private-Equity Funds Buying Biopharma Companies In the 1 years from to 14, private-equity funds acquired pharma companies, mostly in the specialty pharma, generics and OTC fields. Recent larger transactions were the acquisition of US Alvogen by Pamplona in 14 for $7 million, the acquisition of Italian Doc Generici by Charterhouse in 1 for $4 million and the financing of the going private of Swiss Acino in 1 by Avista and Nordic Capital (deal value $4 million). CINVEN purchased two pharma companies in 1: Mercury Pharma for $7 million and Amdipharm for $ million. Interest from PE funds for pharma companies is high. However, with the high prices paid by strategics, buyout funds have not become a major factor yet in biopharma M&A.
9 Upfront Transaction Value ($ billion) HBM Pharma/Biotech Report 14 Trade Sales of Private Biopharma Companies Trade sales of private US & European biopharma companies Trade Sales of Private Biopharma Companies Chart 7: Trade Sales of Private Biopharma Companies VC-backed co's PE-backed co's Other private co's 1 1 $ $ Number or private companies sold $ $. 4 $ $ $ $ incl. $1.7 bn Nycomed/ Takeda incl. $. bn Actavis/ Watson $. 4 $1.. incl. $.7 bn Bausch&L./ Valeant 1. incl. $4. bn Omega/ Perrigo Trade sales of private US and European biopharma companies, not including asset deals or purchases of divisions. Other private companies 11 are companies not majority-owned by venture or private equity funds. $. billion upfront deal value from 4 private transactions. Record upfront transaction volume of $.1 billion for VC-backed trade sales (see pages 1ff). PE-backed pharma company exits have generated over $1 billion of annual transaction volume every year since 1. A list of the larger private transactions can be found on the next page.
10 HBM Pharma/Biotech Report 14 Table : Largest US and European Private Biopharma M&A Transactions in 14 Note: Transactions ranked by upfront value 1
11 Upfront Transaction Value ($ billion) Upfront Transaction Value ($ billion) HBM Pharma/Biotech Report 14 Trade sales of private US & European biopharma companies Trade Sales of Other (Family-Owned) Private Biopharma Companies Chart : Trade Sales of Other Private Biopharma Companies Number of other (family-owned) private companies sold incl. $. bn Hexal/Novartis. 1.. Trade sales of other private US and European biopharma companies. Other private companies are companies that are not mainly owned 1 by venture or Source: private HBM equity Pharma/Biotech funds. Such M&A companies Report are often family-owned. Trade sales of private PE-backed US & European biopharma companies incl. $. bn Stiefel/GSK incl. $. bn Ratiopharm/Teva Trade Sales of Private PE-Backed Biopharma Companies Chart : Trade Sales of Private PE-Backed Biopharma Companies incl. $1.7 bn Nycomed/ Takeda Number of PE-backed private companies sold incl. $. bn Actavis/ Watson Trade sales of PE-backed private US and European biopharma companies incl. $.7 bn Bausch&L./ Valeant incl. $4. bn Omega/ Perrigo 1 Buyout funds took advantage of the good exit environment and sold PE-backed pharma companies in 14, generally with good return multiples. More details on these transactions can be found on the next page. 11
12 HBM Pharma/Biotech Report 14 Trade Sales of Private Equity-Backed Pharma Companies During 14 (ranked by transaction value, headline: Target Company / Buyer / Transaction Value / Business) Omega Pharma (NL) / Perrigo (Ireland) / $4. billion / OTC In November 14, Perrigo Company plc announced the acquisition of Omega Pharma, one of the largest OTC healthcare companies in Europe for. billion or $4. billion. Omega, headquartered in Belgium, generated sales of more than 1. billion in 1. The company had been taken private by Marc Coucke, Belgium's Waterland Private Equity and other investors in 1 in a 4 million ($1.1 billion) deal. Subsequently, Omega purchased some OTC brands from GSK for 47 million. The return for investors on the sale of Omega to Perrigo is estimated be around 4x. Aptalis (US) / Forest (US) /$. billion / Cystic fibrosis, GI In March 14, Forest Laboratories acquired PE-backed Aptalis for $. billion. Aptalis was a global specialty pharma company with about 1 employees worldwide. Aptalis provides innovative therapies for cystic fibrosis and gastrointestinal disorders. Aptalis achieved sales of $ million in FY1 ended September 1. TPG had acquired Aptalis, formerly known as Axcan Pharma, for $1. billion in and merged it with Eurand Pharmaceuticals in 11. The return multiple for TPG is likely to be in the x range. Insight Pharmaceuticals (US) / Prestige Brands (US) / OTC, women s health In September 14, US-listed Prestige Brands acquired Insight Pharmaceuticals for $7 million. Insight, a seller of OTC women s health and personal care products, had been acquired in a secondary buyout in by Swander Pace and Ontario Teachers from Allied Capital, which bought the company in. No terms for the secondary buyout were disclosed, but we guess the 14 exit provided a >x return to investors. Tower Holding (US) / Impax (US) / $7 million / Value-added generics In September 14, US-listed Impax acquired Tower Holding and its operating subsidiaries CorePharma, Amedra and Lineage for $7 million from RoundTable Healthcare. The companies specialized in high value generic formulations including extended-release, delayed-release and DEA controlled substances and the marketing of niche brands. RoundTable had taken a controlling stake in CorePharma in. The amount invested in Tower Holding by RoundTable is unknown. RoundTable likely made an attractive multiple (>x) in this exit. JHP Pharmaceuticals (US) / Par (US) / $4 million /Branded generics In January 14, JHP Pharmaceuticals was sold for $4 million to Par Pharmaceutical Companies, a U.S.- based specialty pharma company. Par is a portfolio company of TPG. JHP Pharmaceuticals, a seller of branded and generics injectables and founded in 7, was acquired by private equity firm Warburg Pincus and Morgan Stanley in 1 in a $1 million transaction. It is estimated that investors in JHP made a.x multiple on this exit. VersaPharm (US) / Akorn (US) $44 million / Generic anti-infectives US niche pharmaceutical company Akorn bought VersaPharm in August 14 for $44 million. Akorn had been acquired in 7 by Tailwind Capital. VersaPharm developed and sold generic products designed to treat tuberculosis and other infectious diseases. No terms of the original buyout are available, so no return estimates can be provided. Archimedes (UK) / Kyowa Hakko Kirin (Japan) / $ million / Specialty pharma Archimedes was acquired in August 14 by Kyowa Hakko Kirin, via its UK subsidiary ProStrakan for million or $ million. Archimedes had been founded in as a specialty pharma company with backing of Warburg Pincus. The company raised over $1 million from Novo Foundation and Warburg Pincus, so the estimated return for PE investors is around x. Acqua Pharmaceuticals (US) / Almirall (Spain) / $4 million / Dermatology In January 14, Spain's Almirall bought Aqua Pharmaceuticals for up to $4 million from PE investor RoundTable Healthcare. Aqua specialised in the development and marketing of drugs for the treatment of skin conditions like acne. 1 sales were around $1 million. RoundTable had taken a controlling stake in Acqua in 1 for undisclosed terms. No return estimates are available. Focus (UK) / Amdipharm Mercury (UK) / deal value undisclosed / Generics, niche medicine In October 14, Amdipharm acquired UK specialty pharma Focus Pharmaceuticals. Financial terms of the transaction were not disclosed. In 7, Matrix Private Equity Partners had financed the m management buyout of Focus Pharmaceuticals. No return estimates are available. 1
13 Upfront Transaction Value ($ billion) Transaction Value ($ billion) HBM Pharma/Biotech Report 14 Trade Sales of VC-Backed Biopharma Companies Trade sales of private VC-backed US & European biopharma companies Trade Sales of VC-Backed Private Biopharma Companies Chart 1/11: Trade Sales of VC-Backed Biopharma Companies 1. Number of VC-backed companies sold Upfront transaction value Overall value With upfront transaction value 4. of at least. $1 million Trade Sales of VC-Backed 7 Private Pharma/Biotech 1 11 Companies Trade sales of private VC-backed US & European biopharma companies Europe Number of European VC-backed co s sold US 17. Number of US VC-backed co s sold Trade sales of private VC-backed US and European biopharma companies 1 Number of VC-backed exits by trade sale is in line with previous years. Upfront and overall biodollar deal values reached new highs. Best exit year for VC-backed US biopharma companies over last decade (see page 17ff). High total deal value in the US ($4. billion upfront, $7. billion including biodollars). European transaction volume down ($. billion upfront, $1.1 billion including biodollars). 1
14 Average Values ($ million) HBM Pharma/Biotech Report 14 Average Deal Values of VC-Backed Biopharma Trade Sales Trade sales of private VC-backed US & European biopharma companies Average Investment / Average Upfront and Overall Deal Values Chart 1: Trade Sales of VC-Backed Biopharma Companies 4 Average Overall Transaction Value Average Upfront Transaction Value Average Invested Capital Trade sales of private VC-backed US and European biopharma companies Only for transactions where respective Record average upfront and total deal values information of was VC-backed available. company exits. Slight decline of average investment amounts. 1 Two Exceptional Deals There was a number of successful US and European exits in 14. Two exceptional US deals are highlighted below: The largest trade sale of a VC-backed biopharma company by far was the sale of Alios BioPharma to Johnson & Johnson for $1.7 billion. Alios focused on the development of novel anti-virals and investors in the company were mainly corporate VC funds. With about $7 million invested, the exit should have returned over x to investors. Another >x exit was the sale of Seragon to Genentech/Roche for $7 million upfront plus up to $1 billion in potential further payments. Seragon had only been founded in 1 as a spin-off from Aragon and had subsequently raised $ million. Its selective estrogen receptor degrader (SERD) program developed for breast cancer was in phase I when the company was sold. 14
15 # of Transactions HBM Pharma/Biotech Report 14 Trade sales of private VC-backed US & European biopharma companies Chart 1: Contingent Biodollar Paymentsas as % of of Overall Total Deal Value % Over % contingent payments Up to % contingent payments No contingent payments 4% 1% 1 % % Average contingent payments in % total deal value 4% 41% 4 Trade sales of VC-Backed US and European companies with total consideration of at least $1 million 4% % 7 1 4% Trade sales of VC-backed private US and European biopharma Only companies for transactions with where >=$1 respective million total deal value. information was available. 17 Comment: Acquisitions of VC-backed biopharma companies, especially pre-commercial ones, are often structured as staged deals, whereby a significant portion (sometimes the majority) of payments are linked to the achievement of certain milestones. Whereas in the years up to, fewer deals were staged, contingent payment structures are now quite common. In 1 and in 1, contingent payments were higher than the upfront payment in over half of the transactions. In 14, the number of deals with such high contingent payments has declined again, probably as a result of a hot exit market. In the period up to, significant contingent payments were mostly seen in earlier clinical stage deals and in deals where investor returns were low (i.e. investors had to accept such deal structures). By contrast, additional earn-out payments are today sometimes demanded by sellers of sought-after companies, providing additional upside on top of an already attractive upfront multiple. 1
16 Ratio / Multiple HBM Pharma/Biotech Report 14 Returns for Venture Investors Trade sales of private VC-backed US & European biopharma companies Average Multiples On Upfront and Total Deal Value Chart 14: Upfront & Overall Deal Values Divided by Invested Capital Weighted-average total multiples * Weighted-average upfront multiples ** Average upfront return estimates ***.1x.x.x.1x.x.1x.7x 1.x.4x.x.x 1.x 1.x 1.4x 1.4x 1.1x 1.x 7.1x.x 4.x.x.7x.1x 1.x.7x.x.x.x.7x x Trade sales of private VC-backed US and European biopharma Only companies. for transactions Calculations where respective are based on transactions where respective information was available. 1 information is available. * Weighted-average total multiples: Aggregate transaction values including contingent payments divided by aggregate investments. ** Weighted-average upfront multiples: Aggregate upfront transaction values divided by aggregate investments. *** Average upfront multiples: Average non-weighted return multiples for investors as estimated by HBM Record upfront and total exit multiples in 14, mainly driven by some great US exits Steadily improving returns since was best exit year for VC backed biopharma companies over the last decade. Comment: We have approximated the return multiples for venture investors from biopharma trade sales using the ratio of upfront proceeds divided by invested capital as a proxy. We have also calculated the potential maximum multiples if all milestones payments were reached. To calculate the average multiples in a given year, we have divided the sum of exit values (upfront or including contingent payments) by aggregate VC investments. These averages weighted by deal size provide in our view a more meaningful indicator of the overall exit performance in a year than non-weighted averages or medians (both of which are generally lower than weighted numbers). 1
17 HBM Pharma/Biotech Report 14 Trade sales of private VC-backed US & European biopharma companies VC-Baked Companies Sold Chart 1: Number Estimated of Pharma/Biotech VC Return Multiples Trade as Estimated Sales by HBM (on Upfront Consideration) 1% % of Transactions 7% % % % Number of transactions Unknown Loss 1x-x x-x x-x >x Only for transactions where respective information was available. Trade sales of private VC-backed US and European biopharma companies. Return multiples on upfront consideration as estimated by HBM (available for about 7% of deals). In 14 (as in 1), close to % of deals had estimated exit multiples of x on upfront proceeds or higher (even when including deals with unknown returns in the total sample). About % of deals had great returns (>x). Before 11, such deals were rare. The number of loss-making transactions appears to be decreasing. 17
18 Ratio / Multiple HBM Pharma/Biotech Report 14 Trade sales of private VC-backed US & European biopharma companies Average Multiples On Total Deal Value US vs. Europe Chart 1: Total Deal Values Divided by Invested Capital US vs. Europe 7 Weighted-average total multiples US Weighted-average total multiples Europe.7x.x.x 4 1.x.x.x.x 4.7x.x 1.7x Trade sales of private US and European VC-backed pharma/biotech Only for transactions companies. where Total respective multiples (including contingent payments) calculated by information was available. dividing total deal value by invested capital, i.e. averages are weighted by deal values. Due to the small number of European data points, we have combined data for two years this analysis. Overall multiples have been steadily increasing in the US. Average total multiples in Europe jumped to.x in 1/14 from a low in 11/1. Another piece of good news is that in the US the average number of years from the company founding to a trade sale exit has dropped from a high of. years average in 11 to. years in 14 (in Europe from. years to.1 years). Please address questions, comments or corrections to the authors of this report: Dr Ulrich Geilinger, Dr Chandra P. Leo, and Emil Bujak, AG, CH- Zug, Switzerland, phone About is among the global leaders in healthcare-focused investing with over USD 1 billion under management. HBM focuses on development stage, growth and buy-out financings of private companies as well as investments in public companies. advises HBM Healthcare Investments AG, HBM BioCapital and further specialized private-equity and public-equity funds. HBM has a complementary team of experienced professionals to source, analyze, execute and exit investments in the pharma/biotech, medical devices and diagnostics industries. has been an active contributor to value creation in its portfolio companies, generating over 4 trade sales and IPOs since inception. More information can be found at 1
January HBM Pharma/Biotech M&A Report Trade Sales of European and North American Biopharma Companies - Key Findings Total (upfront) transaction value reached $. billion (vs. $.6 billion in ), not including
HBM / M&A Survey Trade Sales of nology and Specialty Companies -8 Further information about the survey including a list of transactions can be found under www.hbmpartners.com/survey. The use of data and
HBM Pharma/Biotech M&A Report Trade Sales of Pharma and Biotechnology Companies 05-11 The HBM Pharma/Biotech M&A Report covers all completed trade sales of North American (US and Canada) and European biotechnology,
The Global Biotech Industry: Challenges & Opportunities Michael S. Rosen Rosen Bioscience Strategies Greetings from Chicago! Beaches Yes! Pharma Beginnings! Bogota 1974 Selling Drugs in Colombia Global
: Private equity in life sciences The Colonnade Hotel, Boston, MA October 28, 2008 Industry trends and implications 2 Setting the Stage Overall trends Aging population Emerging market opportunities - access
Back on Track Back on Track The European Perspective E UROPEAN INTRODUCTION Back on Track Europe s biotech industry is decisively back on track. After years of consolidation and relatively stagnant results,
Orphan disease specialists find home with Big Pharma. By Maura Musciacco Senior Analyst January 2013 Tumbling over the patent cliff, many big pharma companies are being forced to find new strategies for
Brochure More information from http://www.researchandmarkets.com/reports/689542/ Biotech Financing in the Credit Crisis: Strategies for a radically altered landscape Description: Introduction: Since the
Life Sciences Outlook New Jersey 2015 New Jersey M&A activity in New Jersey has led to the consolidation of surplus real estate holdings and diminished head counts. However, midsized companies are helping
Raising Capital for Life Sciences Companies US IPOs, Mezzanine Rounds, Strategic Partnerships and License Agreements November 2015 Presented by: Stephen Thau 2 BIOTECH IPOS ARE HOT! The Biggest Biotech
Issue 12 June 21 www.plg-uk.com Business Development & Licensing Journal For the Pharmaceutical Licensing Groups Follow-on biologics Co-marketing: a successful model Trends in dealmaking Finding new products
BIOTECHS: SHOW ME THE MONEY By James R. Gubbins* and Julian Thurston** Money makes the biotech world go around. However, quicker circulation of that cash is driving both trends in new investment in start-ups
State of the Life Sciences Mergers and Acquisitions Market Brian Miller, Managing Partner and Co-Founder, Linden Partners Rich Fante, RF Consulting LLC, Formerly with AstraZeneca Americas Mark Nicholson,
16 th Annual Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum Mergers & Acquisitions: Post-Deal Due Diligence and Integration Challenges October 22, 2015 Corey R. Amundson Assistant
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
Pharma-Biotech Company Valuation - an Introduction Dr. Patrik Frei May 2015 Palermo, Fit for Health 2.0 Overview Company Valuation Break Product Valuation OVERVIEW rnpv PRODUCT VALUATION COMPANY VALUATION
European Biotech & Pharma Dr. Patrik Frei May 2014 Tokyo 1 Overview 1. Venture Valuation 2. Trends in the EU Biotech & Pharma 3. Overview European Biotechs / Clusters 2 Valuation Valuation Mission Independent
H1 2015 Audio webcast RESULTS PRESENTATION July 30, 2015 DISCLOSURE This presentation contains no confidential material and may include publicly available market information which has not been independently
Talentmark Consulting Product Driven People Solutions Press Release The Sage Group and Talentmark Consulting Announce Strategic Alliance for Services to the Global Healthcare & Life Sciences Industry Cambridge
October 2012 Pharma working capital leaves room for improvement 50.7 Billion in Excess Working Capital Ten years ago it was not unusual to be asked why working capital mattered to a pharmaceutical company.
Selling an Idea Dr. Mark McHale Chief Scientific Officer ASLAN Pharmaceuticals Singapore Seminar Format XXXX Know Your Stuff Andy Murray The Beetles Read everything in your field Keep up to date Be dedicated
CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THE STUDY... 1 INTENDED AUDIENCE... 2 METHODOLOGY... 2 ANALYST CREDENTIALS... 2 SCOPE OF REPORT... 2 INFORMATION SOURCES...
GSK Simon Dingemans, CFO Bank of America Healthcare Conference 19 th September 2014 GSK strategy is delivering Focus on innovation and portfolio optimisation to maximise returns Non US/EU sales: 26% in
CORPORATE AND SECURITIES PARIS LLP ddefinitive ADVICE PRACTICAL GUIDANCE POWERFUL ADVOCACY A dedicated team of more than 25 corporate and securities lawyers in Paris who advise French and foreign multinational
Biotech Opportunities for Start-Up Firms in Japan and Asia - Corporate VC s Perspective - Yoshitaka Yoneyama, Ph.D. President & CEO Astellas Venture Management LLC. April 25, 2006 About Astellas Pharma
6 Most countries will experience an increase in pharmaceutical spending per capita by 218 Pharmaceutical spending per capita, 213 versus 218 1,6 1,4 Pharmaceutical Spend per Capita 1,2 1, 8 6 4 2 US Japan
Perrigo Company to Acquire Elan to Create Premier Global Healthcare Company July 31, 2013 Important Information For Investors And Shareholders This announcement does not constitute an offer to sell, or
Brochure More information from http://www.researchandmarkets.com/reports/1878687/ The World's Top 100 Pharmaceutical Companies Description: Did you know? - Dr. Jeremy Levin is Senior Vice President, Strategy,
Quarterly Technology M&A Review Q3 2011 Overall Q3 Technology M&A kept pace with a strong Q2 and proved to be an impressive quarter in terms of both aggregate count and value, totaling 937 announced transactions
Annual Report on Form 20-F 2 Teva at a Glance Founded in 1901 by three young pharmacists, today Teva Pharmaceutical Industries Ltd. is a leader in the global pharmaceutical industry, providing medicines
GCC Pharmaceutical Industry First coordination meeting for the pharmaceutical industry in the GCC and Yemen Dr. Aasim Qureshi 11 April 2011 Global Pharmaceuticals Industry The pharmaceutical industry is
Venture Capital Report Europe 1Q 2016 The following report presents Dow Jones VentureSource s quarterly findings for European venture capital fundraising, investment, valuation, and liquidity. The included
Building Products Industry M&A Outlook Q2 2015 About Us Calabasas Capital is a boutique investment banking firm focused on serving lower middlemarket privately-held companies. We specialize in representing
ZENTIVA S HISTORY Zentiva s transformation over time... ZENTIVA HAS A LONG HISTORY OF PRODUCING HIGH QUALITY PHARMACEUTICALS. TODAY IT IS THE 3 RD LARGEST AND THE FASTEST GROWING GENERICS COMPANY IN EUROPE.
CANADIAN PRIVATE EQUITY BUYOUT REVIEW First Half 2015 REUTERS / Mark Blinch Table of Contents Canada s Buyout & PE Market in H1 2015 3 $ Invested and # Companies Financed 5 Top Buyout Deals 9 Canada by
Press Release 5 th January 215 214 Equity-Backed Buyout Deals and Exits Reach Highest Levels Since the Global Financial Crisis The total value of exits from private equity-backed portfolio companies throughout
EVT Execute & EVT Innovate Leading drug discovery Evotec AG, Nine-month 2015 Interim Report, 10 November 2015 Forward-looking statements Information set forth in this presentation contains forward-looking
Q1 14 Global IPO update January March 214 Table of contents Section Content Slides 1 214 January March* highlights 4 7 2 Global IPO activity trends Global analysis Regional analysis Industry analysis Stock
Investor Growth Capital Stephen Campe Head of Investor Growth Capital Agenda 1. Rationale for Investor Growth Capital and strategy 2. Business overview and setup 3. Our value creation model 4. The portfolio
8 Steps for Analysing Listed Private Equity Companies Important Notice This document is for information only and does not constitute a recommendation or solicitation to subscribe or purchase any products.
//////////////////////////////////////////////////////////////// ASSET MANAGER DEALS: Trends in Asset Manager M&A Five-Year Empirical Deal Study Christopher S. Harrison Schulte Roth & Zabel LLP Negotiating
China Pharma Holdings, Inc. Reports Second Quarter 2010 Financial Results HAIKOU CITY, China, August 10, 2010 China Pharma Holdings, Inc. (NYSE AMEX: CPHI) ( China Pharma or the Company ), a leading fully
Careers in the Pharmaceutical and Biotechnology Industry: Job Classifications and Hiring Needs of the Top Nine Companies, MBS Molly Schmid, Ph.D. Table of Contents Introduction.2 Methodology.. 2 Results
Brilliance in photodynamic technology TM Photocure ASA Exclusive global Licence Agreement for Lumacan with Salix Pharmaceuticals, Inc. 20 October 2010 Kjetil Hestdal, President & CEO Agreement with Salix
Herald Investment Management June 2015 Herald Investment Management Ltd is authorised and regulated by the Financial Conduct Authority This presentation is intended for professional investors only Investors
DPP - DSM in motion: driving focused growth DSM and JLL create leading pharma services company in US$ 2.6bn transaction 19 November 2013 Page Safe harbor statement This presentation may contain forward-looking
IMF COMMITTEE ON BALANCE OF PAYMENTS STATISTICS AND OECD WORKSHOP ON INTERNATIONAL INVESTMENT STATISTICS DIRECT INVESTMENT TECHNICAL EXPERT GROUP (DITEG) ISSUE PAPERS #4, #28, #29 MERGERS AND ACQUISITIONS
M&A Leaks Issues of Information Control August 2009 1 866 INTRALINKS New York + 1 212 342 7684 London + 44 (0) 20 7060 0660 Hong Kong + 852 3101 7022 www.intralinks.com Thinking from IntraLinks Foreword
Careers in the Pharmaceutical Industry - what really counts - Dr. Wolfgang Haupt Novartis Vaccines & Diagnostics, Marburg, Germany Agenda Section 1 Overview on the Top Ten Pharmaceutical Companies Section
Entity Principal activities Global Revenue Activities in Ireland Accenture plc Accenture PLC is a multinational management consulting services company. Its incorporated headquarters have been in Dublin,
Domanda di innovazione nel mondo industriale. Modalità di interazione tra pubblico e privato Ennio Ongini Nicox Consiglio Nazionale delle Ricerche Quarta Giornata Informativa "Dalla ricerca al Trasferimento
1Q 2016 Access Affordable Pharma VanEck Vectors Generic Drugs ETF (GNRX) ETF disclosure This material does not constitute an offer to sell or solicitation to buy any security, including shares of any fund.
Press Release Paris, 11 February 2016 Financial information - 3 rd quarter and 9 months 2015/2016 Strong improvement in third quarter revenue, up 26% on 2014/2015 9 months revenue showed good growth at
Sales Force Effectiveness in Pharmaceuticals Targeted Sales Models such as Enhanced Key Account Management (KAM) and Closed-Loop Marketing (CLM) Strategies Drives Sales Force Efficiency GBI Research Report
Germany Reports Record High of New Investment Projects Germany is a very attractive location for foreign investors. Germany Trade & Invest (GTAI) and the economic development agencies of the German Federal
www.pwccn.com Private Equity / Venture Capital 215 Review and 216 Outlook 3 March 216 Table of contents Fund raising 3 Investments 8 Exits 15 216 outlook 22 Fundraising PE and VC fundraising remained at
Brochure More information from http://www.researchandmarkets.com/reports/344881/ The Future of Monoclonal Antibodies Therapeutics: Innovation in Antibody Engineering, Key Growth Strategies and Forecasts
CHEM-E4140 Selectivity 12. Pharma Business Prof. Ari Koskinen Laboratory of Organic Chemistry C318 Pharma Business Total volume ca 1100 G$ (Shell 421G$; Walmart 486G$; Toyota 252 G$). Annually approx 25
Strong Momentum in Healthcare: Trends in Mergers and Acquisitions WRITTEN BY Jonathan Norris Managing Director Silicon Valley Bank t 5 9 1 email@example.com HEALTHCARE MERGERS AND ACQUISITIONS MAINTAINED
Company Research and Analysis Report FISCO Ltd. http://www.fisco.co.jp 伪 伪 Focusing on improving technology to obtain antibodies using the fully human ADLib system (4583) (subsequently, the company ) is
Key Findings The global autoimmune market generated sales of $31.9bn in, an increase of 14.4% over 2006 sales. The market is forecast to grow at a CAGR of 8.1% to reach a total value of $51.0bn in 2013.
Pernix Therapeutics Holdings Reports Third Quarter 2011 Financial Results November 15, 2011 12:55 PM ET Net Revenues Increased 120% to $17.1 Million from $7.8 Million in the Third Quarter of 2010 Strong
Biotechgate: European Life Sciences Database Biotech & Medtech Survey Patrik Frei Zurich, June 16th 005, Biotechgate: a European Biotech Database A European Biotech () database, fed by country Databases
M&A Watch: Hospitals seeking mergers with bigger players can be choosier By Beth Kutscher January 24, 2015 It has taken Rockford (Ill.) Memorial Hospital more than three years and three attempts to find
Public funding policies: which options for small innovative companies in 2009 Biotech SMEs in the EU: how to improve access to finance Dirk Carrez Director, EuropaBio EuroBio - 25 September 2009 (Lille)
Clinical trial research agreement Agreed schedule 4 or 7 clause amendments Medicines Australia and Medical Technology Association of Australia templates The sponsors in the table have agreed clauses for
Innovative genetics research and biomarker solutions to advance molecular medicine Corporate Overview April 2013 1 Oxford Gene Technology (OGT) Advancing molecular medicine Well-established private genomics
Orphan Pharma: pathfinders for an increasingly specialised industry Foreword We are continuing our series by profiling the R&D and Clinical Development leadership of European and North American specialty
Major 3-part Transaction with Novartis Investor Presentation 22 nd April 2014 Andrew Witty Chief Executive Officer Transaction highlights Major 3-part transaction with Novartis to drive sustainable sales
Dermatology Opportunities for Mid-sized Pharmaceutical Companies Photocure Capital Markets Day 28 October 2009 John Rountree Partner NovaSecta Limited 137 Euston Road London NW1 2AA, UK http://www.novasecta.com
J.P. Morgan 2016 Healthcare Conference Tom Pike CEO January 12, 2016 Copyright 2016 Quintiles NYSE: Q Forward Looking Statements and Use of Non-GAAP Financial Measures This presentation contains forward-looking
TRANSITION TO A COMMERCIAL AND PROFITABLE PHARMACEUTICAL COMPANY CONTINUES Presenting at Småbolagsdagen June 10, 2013 LEGAL DISCLAIMER This presentation, which is personal to the recipient, has been prepared